HTA outcome for ATMPs in the three Scandinavian countries Sweden, Norway, Denmark

What is the outcome of ATMPs that has been approved by the EMA in the Scandinavian markets?
Read now
What is the Future of Rare Disease Research and Development in the EU?
Rare diseases are a major public health issue in the European Union (EU), affecting an estimated 30 million people, or between 6% and 8% of the population. (1)
Valtermed: The Spanish National Health System’s information system that collects real world evidence on the therapeutic value of new therapeutics
In recent years, new pharmaceutical policies have been implemented in the Spanish National Health System (NHS) aiming to restrain pharmaceutical spending and improve transparency in healthcare decision making. Among them, there has been an increase in the use of performance-based agreements at national and regional level, as well as the development of the Valtermed program.
More price negotiations on new expensive drugs in the Netherlands
On the 24th of January 2023, the Dutch Minister of Health, Welfare and Sport Ernst Kuipers has decided to adapt the rules for admission of expensive (intramural) medicines to the basic health insurance package as from 1st July 2023. He is doing this by tightening the so-called lock criteria.
The AIFA’s innovativeness appraisal for medicines
A standardized procedure to evaluate the innovativeness of medicines has been implemented by the Italian Medicines Agency since 2017 (AIFA - Determina n. 1535/2017).